Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Diluted Average) (2020 - 2025)

Spyre Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $346045.0 for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 7.57% year-over-year to $346045.0; the TTM value through Dec 2025 reached $346045.0, down 7.57%, while the annual FY2025 figure was $346045.0, 7.57% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $346045.0 in Q4 2025 per SYRE's latest filing, down from $60.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $82.2 million in Q2 2022 to a low of $346045.0 in Q3 2024.
  • Average Shares Outstanding (Diluted Average) over 5 years is $23.7 million, with a median of $3.8 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): tumbled 95.35% in 2023, then skyrocketed 17336.62% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $2.6 million in 2021, then skyrocketed by 43.28% to $3.8 million in 2022, then skyrocketed by 83.05% to $6.9 million in 2023, then crashed by 94.57% to $374387.0 in 2024, then fell by 7.57% to $346045.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Shares Outstanding (Diluted Average) are $346045.0 (Q4 2025), $60.3 million (Q3 2025), and $60.3 million (Q2 2025).